Joachim Yahalom, MD
New York, NY
Memorial Sloan Kettering Cancer Center
MD- Hebrew University, Jerusalem. Residencies and Fellowships in Clinical and radiation Oncology in Israel and Memorial Sloan-Kettering. Armored Brigade Physician (Major), IDF, project leader R&D branch, IDF.
Attending and Member, MSKCC. Co-Leader Lymphoma DMT, Chief- Radiation Hematology Service. Hodgkin and Non-Hodgkin NCCN guidelines committees.
Chairman of the International Lymphoma Radiation Oncology Group (www.ilrog.org) -over 1300 members in 75 countries.
Clinical Research focus on role of RT in salvage of lymphomas, breast cancer after chest RT, combined modality in PCNSL, RT for gastric MZL. Currently- clinical and biological aspects of sub-lethal radiation for lymphomas; role of RT to improve CAR-T cell therapy.
Translational research interest: Past- ATM mutations and risk of second cancers; autophagy as a mechanism for tumor cell death after radiation. Present- mechanisms and predictors of lethal effects of very low-dose RT on lymphoma cells and their environment.